Q4 2025 Syndax Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Syndax Pharmaceuticals Inc (SNDX) achieved robust financial results in 2025, with total revenue reaching $172 million, driven by successful launches of Revuforj and Niktimvo.
- Revuforj generated $125 million in net revenue in its first full year, with a 38% growth in the fourth quarter, indicating strong demand and market penetration.
- Niktimvo's net revenue reached $152 million in 2025, surpassing benchmarks set by similar drugs, highlighting its effectiveness in addressing fibrosis and inflammation.
- The company achieved its third FDA approval within a year, demonstrating strong R&D capabilities and regulatory success.
- Syndax Pharmaceuticals Inc (SNDX) is well-funded with $394 million in cash and marketable securities, positioning it to continue investing in strategic growth initiatives without needing additional capital.
- Despite strong revenue growth, the company faces competition in the menin inhibitor market, which could impact future market share and growth potential.
- The average treatment duration for Revuforj in 2025 was in the four- to six-month range, which may limit long-term revenue potential if not extended.
- The company anticipates stable expenses of approximately $400 million in 2026, which could pressure profitability if revenue growth does not meet expectations.
- There is uncertainty regarding the competitive landscape for axatilimab in IPF, with other therapies targeting similar pathways potentially impacting market entry and success.
- The company is reliant on successful clinical trial outcomes for future growth, particularly in expanding indications for Revuforj and axatilimab, which carry inherent risks.
Good day, everyone, and welcome to the Syndax fourth-quarter 2025 earnings conference call. Today's call is being recorded. (Operator Instructions)
At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Thank you, operator. Welcome, and thank you, all, for joining us today for a review of Syndax's fourth-quarter and full-year 2025 financial and operating results. I'm Sharon Klahre, and with me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer; Steve Closter, Chief Commercial Officer; Dr. Nick Botwood, Head of R&D and Chief Medical Officer; and Keith Goldan, Chief Financial Officer.
This this call is accompanied by a slide deck that has been posted on the Investor page of the company's website. You can now turn to our forward-looking statements on slide 2.
Before we begin, I'd like
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
